ACS medicinal chemistry letters
January 11, 2024
Robert B. Kargbo
1 citation
Psychedelic compounds such as ketamine and LSD promote neuronal growth by activating AMPA receptors, TrkB, and mTOR, acting as psychoplastogens. The prefrontal cortex exerts top-down control over brain regions involved in motivation, fear, and reward, contributing to therapeutic effects. These compounds enhance synaptic plasticity and neurogenesis, producing antidepressant effects, and modulate fear circuits to provide anxiolytic properties. They also disrupt addictive patterns and promote neuroplasticity, showing promise as anti-addictive agents. This exploration reveals new opportunities for treating major depressive disorder, anxiety, and addiction.
ACS Medicinal Chemistry Letters
July 10, 2026
Anna C. Renner, Robert B. Kargbo
The psychedelic therapeutics field is moving beyond classical hallucinogens to integrated treatment platforms that combine optimized pharmacology, drug delivery, and clinical implementation. Recent patent applications describe selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds, and structured 5-MeO-DMT treatment regimens for depression. These innovations represent a convergence toward scalable, safer, and clinically practical neuropsychiatric therapies that may reshape the future of serotonergic medicine.
ACS Medicinal Chemistry Letters
December 16, 2025
Anna C. Renner, Robert B. Kargbo
Three new approaches in neuropsychiatric therapeutics are converging: a blood test measuring FOXG1 gene expression for objective PTSD detection; benzocyclobutenyl-methylamine compounds that reduce excessive neuronal firing; and a sublingual 5-MeO-DMT formulation that promotes neuroplasticity without hallucinations. These advances link molecular diagnostics, targeted neural circuit modulation, and scalable treatments for affective disorders.
ACS Medicinal Chemistry Letters
December 16, 2025
Anna C. Renner, Robert B. Kargbo
Recent inventions create a framework for safer, more reliable psychedelic medicines. Simplified iboga analogs offer tunable polypharmacology, real-time EEG biomarkers personalize psilocybin dosing, and standardized harmine-DMT ratios achieve high bioavailability. These innovations improve mechanistic precision, receptor selectivity, and pharmacokinetic control.
ACS Medicinal Chemistry Letters
October 10, 2025
Anna C. Renner, Robert B. Kargbo
A new crystalline cocrystal combining psilocin and psilocybin increases drug exposure, boosts markers of neuroplasticity, and alters functional brain activity. Adding atypical antipsychotics to the treatment changes serotonin signaling, reducing safety risks linked to the 5-HT2B receptor, which is associated with heart valve problems. These chemical advances improve how the therapy works, its selectivity for desired effects, and the ability to measure its impact in lab models. Together, they offer a chemistry-based way to develop scalable psychedelic treatments that are safer for the heart and produce lasting neuroplastic changes, as shown in organoid and animal studies.
ACS Medicinal Chemistry Letters
August 15, 2025
Robert B. Kargbo
Certain novel compounds, including psilocybin, show promise for treating psychiatric conditions through unique pharmacological actions. By modifying their chemical structure, researchers can achieve functional selectivity at serotonin (5-HT) receptors, reducing hallucinogenic effects while maintaining therapeutic benefits. The work combines receptor-level and behavioral evidence to support these compounds as rational treatments for demoralization syndrome and depression-related disorders.
ACS medicinal chemistry letters
June 12, 2025
Robert B. Kargbo
New non-hallucinogenic compounds based on substituted tryptamines show promise for treating metabolic and neuropsychiatric disorders by selectively targeting 5-HT2A/2C receptors. Two recent patent applications describe analogs that avoid psychedelic effects while offering optimized receptor selectivity, potential metabolic benefits, and the ability to promote neuroplasticity. These agents represent a novel chemical framework for multimodal treatment strategies in brain disorders and metabolic health.
ACS medicinal chemistry letters
April 10, 2025
Robert B. Kargbo
Psychedelics and artificial intelligence both alter cognitive frameworks, disrupt rigid thinking, and boost neuroplasticity, which may help treat depression, PTSD, and addiction. By relaxing neural filters, they induce altered states of consciousness that challenge how reality is perceived. This viewpoint examines the neurobiological mechanisms behind these effects and considers how AI could enhance psychiatric treatments.
ACS medicinal chemistry letters
April 10, 2025
Robert B. Kargbo
Advancements in psychedelic therapeutics, tryptamine derivatives, neuroplastic modulators, and AI-powered machine-learning platforms are opening new possibilities in precision medicine. These innovations target neurological and psychiatric disorders, chronic pain, and computational accessibility through receptor modulation, targeted delivery, and simplified AI integration. They promise transformative solutions for patient care and technological development.
ACS Medicinal Chemistry Letters
April 10, 2025
Robert B. Kargbo
Psilocybin reduces phantom and residual limb pain by a clinically meaningful amount. Adaptive sensory environments (ASEs) use biosensors to guide modulation of psychological states during psychoactive therapy. This Patent Highlight reviews pharmacological findings from a psilocybin trial and discusses future integration with ASE systems to improve precision and scalability of psychedelic-assisted interventions.
ACS medicinal chemistry letters
February 13, 2025
Robert B. Kargbo
Combining monoamine antidepressants with short-duration psychedelics like DMT and psilocybin, alongside AI-driven behavioral tracking, may offer rapid and sustained improvements for treatment-resistant depression and anxiety. AI-enhanced monitoring uses motion tracking and machine learning to quantify outcomes in animal models, speeding drug development. These approaches aim to personalize psychiatric care.
ACS medicinal chemistry letters
December 12, 2024
Robert B. Kargbo
Psychedelic compounds like psilocybin and psilocin show therapeutic promise for neurological and psychiatric disorders, but their clinical use is limited by poor bioavailability, rapid metabolism, and stability issues. This Patent Highlight reviews recent innovations in drug delivery systems and psilocin analogs, including controlled-release systems, ester analogs, and acetal/ketal derivatives. These patents present novel approaches to improving stability, bioavailability, and efficacy, potentially leading to more effective treatments for depression, chronic pain, and neurodegenerative diseases.
ACS Med Chem Lett
November 11, 2024
Robert B. Kargbo
Three new classes of psilocin-related compounds—4-pivaloyloxy-N-methyltryptammonium chloride, alkyl quaternary ammonium tryptamines, and 4-pivaloyloxy-N-methyltryptammonium derivatives—have been developed to improve stability, bioavailability, and efficacy for treating depression, anxiety, and substance use disorders. Preclinical studies indicate these innovations may overcome limitations of traditional psychedelics, offering more reliable therapeutic options for mental and neurological disorders.
ACS Medicinal Chemistry Letters
August 21, 2024
Robert B. Kargbo
A review of three patent applications examines the potential of entheogens such as psilocybin to treat cognitive decline and bolster psychological resilience in patients receiving anesthesia or sedation. The article describes proposed therapeutic mechanisms, treatment methods, and possible clinical outcomes for postoperative care. It provides an overview of this emerging approach without presenting original data or empirical findings.
ACS Medicinal Chemistry Letters
August 21, 2024
Robert B. Kargbo
Recent psychedelic research has produced lysergic acid derivatives with modified LSD-like effects, a psilocybin dosing method guided by ABCF1 gene expression, and new treatments for binge eating disorder. Neuroenhancement techniques that boost emotional responses are also being explored. These developments point toward personalized medicine and expanded mental health applications, signaling a transformative phase in clinical psychedelic use.
ACS medicinal chemistry letters
March 14, 2024
Robert B. Kargbo
Recent innovations in neurostimulation, psychedelic therapy, and brain function optimization are advancing personalized brain therapy. Methods for altering brain states include AI-driven non-invasive neurostimulation. The therapeutic potential of N-isopropyl tryptamines and tryptamine derivatives is examined, alongside psilocybin and psilocin crystalline forms for mental health and central nervous system disorders. These diverse approaches are compared for their mechanistic insights and therapeutic implications, contributing to neuroscience and mental health.